Femasys (NASDAQ:FEMY) Given Buy Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Chardan Capital decreased their price target on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Femasys Price Performance

Shares of FEMY traded down $0.10 during midday trading on Tuesday, hitting $1.07. The company’s stock had a trading volume of 210,182 shares, compared to its average volume of 333,051. The company has a quick ratio of 5.93, a current ratio of 6.47 and a debt-to-equity ratio of 0.43. Femasys has a one year low of $0.73 and a one year high of $2.40. The stock has a market capitalization of $23.68 million, a price-to-earnings ratio of -1.28 and a beta of -2.83. The company’s fifty day simple moving average is $1.17 and its two-hundred day simple moving average is $1.15.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Femasys stock. Aljian Capital Management LLC acquired a new position in Femasys Inc. (NASDAQ:FEMY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned approximately 0.11% of Femasys at the end of the most recent quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.